2022
DOI: 10.3390/cancers14205019
|View full text |Cite
|
Sign up to set email alerts
|

Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer: Current Techniques and Future Trends

Abstract: Bladder cancer (BC) is the 10th most common cancer globally and has a high mortality rate if not detected early and treated promptly. Non-muscle-invasive BC (NMIBC) is a subclassification of BC associated with high rates of recurrence and progression. Current tools for predicting recurrence and progression on NMIBC use scoring systems based on clinical and histopathological markers. These exclude other potentially useful biomarkers which could provide a more accurate personalized risk assessment. Future trends… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
6
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 111 publications
0
6
0
Order By: Relevance
“…Because noninferiority is evaluated with respect to a ground‐truth measurement, it will be difficult to prove the utility of AutoParis‐X to assign specimen atypia based on alignment to cytopathologist ratings alone given the high interobserver variation (e.g., there is no universal, quantitative ground truth in UC) 12,17,89 . Additional validation will likely require an assessment of its capacity to predict more objective outcomes, such as disease recurrence or death 92–95 . In addition, its cost effectiveness over traditional methods will also need to be proven (e.g., Current Procedural Terminology codes, relative value units, the number of specimens per day, technologist and pathologist time spent), which will communicate revenue to be expected/workforce needed when operating the device 96–99 .…”
Section: Discussionmentioning
confidence: 99%
“…Because noninferiority is evaluated with respect to a ground‐truth measurement, it will be difficult to prove the utility of AutoParis‐X to assign specimen atypia based on alignment to cytopathologist ratings alone given the high interobserver variation (e.g., there is no universal, quantitative ground truth in UC) 12,17,89 . Additional validation will likely require an assessment of its capacity to predict more objective outcomes, such as disease recurrence or death 92–95 . In addition, its cost effectiveness over traditional methods will also need to be proven (e.g., Current Procedural Terminology codes, relative value units, the number of specimens per day, technologist and pathologist time spent), which will communicate revenue to be expected/workforce needed when operating the device 96–99 .…”
Section: Discussionmentioning
confidence: 99%
“…there is no universal, quantitative ground truth in urine cytology) 12,17,93 . Additional validation will likely require assessment of its capacity to predict more objective outcomes, such as disease recurrence or death [96][97][98][99] . Additionally, its cost-effectiveness over traditional methods will also need to be proven (e.g., CPT codes, RVUs, number of specimens per day, technologist and pathologist time spent), which will communicate revenue to be expected / workforce needed when operating the device [100][101][102][103] .…”
Section: Discussionmentioning
confidence: 99%
“…Urothelial carcinoma ranks ninth worldwide in cancer incidence as the seventh most common malignancy in men and seventeenth in women [1][2][3] . In the United States, urinary bladder cancer (UBC) is the fourth most common cancer in men and tenth in women.…”
Section: Introductionmentioning
confidence: 99%